Professor David Goldstein is a conjoint clinical professor at UNSW with an extensive track record in novel therapeutics trials and clinical research into pancreatic cancer, GIST, psychosocial care (particularly migrant populations), treatment-related toxicity and cancer survivorship. He is the Director of the UNSW Translational Cancer Research Network, a $6,000,000 CINSW funded program. He is the adult program leader of the UNSW National Cancer Survivors Centre and is involved with a research program associated with survivorship issues. As part of this activity, he is the Chief Investigator of a Cancer Institute NSW translational program grant to study the impact of chemotherapy induced peripheral neuropathy. Prof Goldstein has 300 co-authored peer reviewed publications and presented in many national and international meetings. Professor Goldstein is a founding member of the NSW Pancreatic Cancer Network, has been a member of the Australian Gastro-Intestinal Trials Group Scientific Advisory Committee for the last 12 years, a board member of the Gastro-Intestinal Cancer Institute for nine years and the longest serving president of the Clinical Oncology Society of Australia (COSA). He is a member of the ASCO Asia Pacific Council and the NCI Hepatobiliary task force. He was on the International Committee of the American Society of Clinical Oncology for a 3 year term and subsequently joined the ASCO/ HVO [health volunteers abroad] international oncology program. He was the project leader for the ASCO/HVO cancer program in Hue Vietnam, and is now the chair of the supervisory committee of all HVO cancer projects. He was awarded the Peoples Health Medal by the National Department of Health of Vietnam, for his work there in contributing to enhanced cancer care.